Evidence map›Paper›PMID 26724834›Full record

ArticleClinical lymphoma, myeloma & leukemia2016

Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria.

Catherine C Coombs, Lisa M DeAngelis, James H Feusner, Jacob M Rowe, Martin S Tallman

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  11. Review
  12. Review
  13. Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey.Mediterranean journal of hematology and infectious diseases · 2018
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Catherine C CoombsLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Lisa M DeAngelisDepartment of Neurology, Weill Cornell Medical College, New York, NY; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
James H FeusnerDepartment of Pediatric Hematology/Oncology, Children's Hospital and Research Center Oakland, Oakland, CA.
Jacob M RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: tallmanm@mskcc.org.
Cornell University · USMemorial Sloan Kettering Cancer Center · USShaare Zedek Medical Center · IL

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer CenterU10CA180791 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AGHAJANIAN, CAROL, MORRIS, MICHAEL J · 2014 to 2018
$4.6M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180791
6 · The paper itself

Abstract

backgroundMultiple randomized trials have demonstrated a benefit for all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL). Pseudotumor cerebri (PTC) is an infrequently reported adverse effect of ATRA.

methodsWe examined the incidence, clinical course, and outcomes of patients with APL treated on Intergroup Protocol 0129 (I0129) who developed PTC. This trial evaluated the role of ATRA alone during induction and/or as maintenance therapy.

resultsOf the patients on trial, 240 received ATRA during induction, maintenance, or both; 8 had a clinical suspicion for PTC. Upon review of individual cases, this was felt to be "probable" in 4 patients, "possible" in 1 and "unlikely" in 3 due to lack of diagnostic criteria or presence of a more likely alternate diagnosis.

conclusions"Probable" PTC occurred in 1.7% of patients who received ATRA during induction and/or maintenance therapy. In agreement with previous reports, the incidence of PTC in APL patients receiving ATRA was higher in the pediatric population. Here, we discuss the method for diagnosing PTC in the setting of ATRA therapy and management strategies.

Indexed as

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolFemaleHumansIncidenceInduction ChemotherapyLeukemia, Promyelocytic, AcuteMaintenance ChemotherapyMalePseudotumor CerebriRandomized Controlled Trials as TopicTreatment OutcomeTretinoinTretinoinAcute promyelocytic leukemiaAll-trans retinoic acidATRANeurotoxicityPseudotumor cerebri

Identifiers

PMID26724834
PMCPMC5028896
OpenAlexW2173574404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.